National volume procurement after the arms enterprises can be such a transformation

high-value medical supplies and other medical supplies of the national procurement, tender, will be the same as the national procurement of drugs, bidding, become regular, institutionalized 1, the second and third batch of high-value consumption Material collection will hitthe first batch of high-value medical supplies after the national harvest, followed by the second batch, the third batch of high-value medical supplies of state-level bidding collection, this is a trend, who can not stop.Its purpose is to significantly reduce the purchase price and consumption price of high-value medical supplies, completely eliminate the gray income in the circulation link, so that the original high-priced medical supplies, become thousands of ordinary patients can afford the product.For a long time, high-value medical supplies in the top of patient consumption, sick, who do not want to recover early, who do not want to use a better medical supplies, but for ordinary people, some people can not afford? tens of thousands, even hundreds of thousands, hundreds of thousands, astronomical prices. It is also possible to import, the price is more vague, the variety of product regulations are also less, resulting in a rare and expensive phenomenon.As agents in order to promote these high-value medical supplies, it is reasonable to design layers of costs, the price should be raised, because we all know the truth of wool out of sheep.Fortunately, all of this will gradually disappear with the national harvest, high-value medical supplies and other medical supplies of national mining, bidding, with the national procurement of drugs, bidding will become routine, institutionalized. This regulates the product in the pharmaceutical field, from production to procurement to the use of the entire industrial chain price system operating process.

2, the business model of armed enterprises urgently need to break throughSpecialized medical supplies operating companies, or large pharmaceutical companies of the medical equipment department, is operating all kinds of medical supplies of the main body. Originally independent operation, directly with the production enterprises or large varieties of agents to negotiate distribution agreements, to become a province or a region of the distribution agents, distribution prices are agreed between the two sides in accordance with the needs of the market and the value of the varieties themselves.Such a model has been continued for several years, now no longer exists, because the pricing power of products is not entirely in the hands of production enterprises themselves, must be tendered, collected, some products also entered the catalog of national mining. That must go through the relevant departments to negotiate, all production costs, circulation costs, corporate profits and financial taxes will be put in the sun to measure, but also with the same industry, the same varieties of competition, and finally determine an appropriate price.During this period, as a commercial company operating medical supplies is not involved in the price setting, so when the price set by the state, and then by the commercial company to distribute, operate, pharmaceutical commercial companies how to do. The original business model obviously did not work, because there is no such a large cost space, the water in the middle is basically squeezed out.That has to be done, for the entire industrial chain, there is no less than the middle of the distribution of this ring, because the production enterprises are not yet able to all end customers (hospitals at all levels) distribution.And now most of the logistics courier companies do not have the qualifications of pharmaceutical distribution, because drugs and medical supplies are special commodities, involving the physical and mental health of ordinary people, not all logistics courier companies can bear the business.

3, these directions will become pathIn order to adapt to the distribution of high-value medical supplies and all medical supplies in the future, commercial companies should adjust the current sales model, with specialized services instead of traditional cost convergence, in order to expand sales volume to reduce their operating costsIn the high-value medical supplies after the national harvest, not to say whether to pharmaceutical commercial company's distribution, but how to distribute, in what way distribution, pharmaceutical commercial company's bridge as at least in the short term will not be cut, but to be strengthened in the new situation.Of course, not all pharmaceutical commercial companies, can be divided into the country after the distribution of this piece of pie.Because in practice, a large proportion of pharmaceutical commercial companies do not have and do not want to change the current business thinking, that is certainly to be in the national distribution sequence out.And the pharmaceutical commercial companies that really win the right to distribute must be the new pharmaceutical commercial companies that stand at the top of the times and are indisputable. (Cypress Blue Equipment)